Projection Mapping Showcase of "YOASOBI / 'Idol’” Premiered Saturday, December 14!
20.1.2025 04:14:00 CET | Business Wire | Press release
~ Over 450,000 Visitors Have Experienced "TOKYO Night & Light" ~
The Tokyo Metropolitan Government has been hosting year-round projection mapping displays at the iconic Tokyo Metropolitan Government Building (No. 1 Building). These displays use light and sound to create vibrant and diverse works of art, transforming the landmark into a new tourism resource that illuminates Tokyo’s nightscape. The event began in February of 2024 and has been visited by approximately 450,000 people to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250107191600/en/
YOASOBI / 'Idol’ (Photo: Business Wire)
Recently, a new projection mapping work featuring YOASOBI's globally acclaimed song "Idol" premiered on Saturday, December 14. The opening day saw a large number of visitors from both Japan and abroad, creating an exciting atmosphere befitting such a popular attraction.
Feedback from attendees included comments such as, "I came to Japan as a tourist, and after seeing the weekday version, I wanted to see the weekend version as well, so I came back," "This is the most powerful projection mapping I've ever seen -- it was truly moving," and "YOASOBI's new content had a retro vibe, which I really enjoyed. I don’t think you’d see something like this very often overseas.”
Visitors can enjoy projection mapping videos created by renowned domestic and international creators, who have been highly praised at international competitions. This event is quickly evolving into one of Tokyo's must-visit tourist attractions. With its exceptional artistry, cutting-edge technology, and world-class content, this "new nighttime tourism hotspot that lights up Tokyo's nights" is one to watch.
Overview of the Work | YOASOBI / "Idol"
The song "Idol" by YOASOBI, which gained widespread attention as the theme song for an anime, is a masterpiece that blends rhythmic and vibrant elements with themes of uncertainty and inner conflict. The projection mapping display brings the emotional nuances of this song to life, offering an immersive visual and auditory experience.
Creator: Yukihiro Oka (Japan)
* Please visit our website for the screening schedule.
https://tokyoprojectionmappingproject.jp/en/
About the song
YOASOBI’s hit song "Idol" broke records by surpassing 800 million cumulative streaming plays in the shortest time ever. It topped several major global charts, including the U.S. Billboard Global Chart “Global Excl. U.S.,” Apple Music’s “Top 100: Global,” and YouTube Music Charts TOP 100 Songs Global, setting unprecedented milestones in J-POP history.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107191600/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom